Datavault AI Expands Blockchain Licensing Deal, Takes 19.9% Stake in Datameds AI
DVLT sits 33% above its 52-week low of $0.251.
Summary
Datavault AI is expanding its blockchain technology licensing agreement with Datameds AI and will receive a 19.9% equity stake in the company upon closing. This deepens an existing partnership and adds a direct ownership interest, signaling commitment to the blockchain vertical. The deal follows a series of aggressive moves by Datavault, including a $2B financing term sheet and a $50M Bitcoin sale, as it pivots toward AI and digital assets. The equity stake could provide upside if Datameds AI grows, but terms of the license expansion and any cash consideration remain undisclosed. With a market cap near $280M and a stock price at $0.34, this partnership adds a new growth vector but lacks immediate financial impact details.
Updates
· FinanceWire — The expanded license moves PharmacyChain into commercial healthcare, healthspan, and wellness, and the 19.9% stake replaces preferred shares for tax optimization.
At the time of this announcement, DVLT was trading at $0.34 on NASDAQ in the Technology sector, with a market capitalization of approximately $280.6M. The 52-week trading range was $0.25 to $4.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.